Please login to the form below

roxadustat

This page shows the latest roxadustat news and features for those working in and with pharma, biotech and healthcare.

AZ preps new roxadustat filings, though data foxes investors

Comes with increased blood pressure warning label. AstraZeneca and FibroGen say they are preparing a US filing of roxadustat for anaemia in chronic kidney disease after reporting cardiovascular outcomes data from ... There is a significant unmet medical

Latest news

First-line ovarian approval cements AZ’s Lynparza lead

And in another positive development, AZ also announced today that two additional phase 3 trials of its just-approved drug for anaemia in chronic kidney disease patients – roxadustat – backed the efficacy
China first market to approve AZ’s kidney drug roxadustat

Roxadustat was compared to treatment with epoetin alfa over 26 weeks, matching the ESA’s efficacy in achieving a significant increase in haemoglobin levels. ... AZ and FibroGen have rights to roxadustat in the US, China and other world markets, while
AZ, FibroGen's anaemia drug on course for first filing this year

Roxadustat works by turning on the body's machinery for producing red blood cells that is usually stimulated by reduced oxygen levels in the blood. ... In addition, use of roxadustat is free of the burden of cold-chain storage and maintaining sterility,
GSK starts late-stage trials of daprodustat

administration.". GSK is in a race to market with other HIF-PHI developers, including FibroGen, which has a candidate called roxadustat (FG-4592) in late-stage trials in China for anaemia ... FibroGen said recently it is on track to file a marketing
AZ boosts cardio-renal portfolio with $2.7bn ZS Pharma buy

ZS-9 alongside drugs such as roxadustat, which is currently in phase III testing for anaemia associated with CKD.

More from news
Approximately 1 fully matching, plus 5 partially matching documents found.

Latest Intelligence

Orphan drugs and breakthrough therapies drive Cortellis Drugs to Watch 2019

The sales forecast for Zolgensma is $2.09bn. Roxadustat, from AstraZeneca, FibroGen and Astellas, targets anaemia in chronic kidney disease (CKD).
China: AstraZeneca’s new engine for growth and innovation

Roxadustat is under accelerated review and, if approved, would also be the first locally- developed medicine to hit the Chinese market even before Europe and the US,” says Mallon. ... Finally, a data readout for roxadustat is expected by the end of 2018

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Featured jobs

FREELANCE Account Director – Healthcare Advertising – London – 3...: Competitive Daily Rates

Strategic Planner, Healthcare Advertising Agency: Salary TBC

Account Director - Healthcare Advertising - London - 2 DAYS HOME...: £50000 - £70000

FREELANCE Medical Writer (Initial 2/ 3 months term) - London Off...: Excellent Daily Rate

Account Director – UK Office: Excellent salary and benefits

Senior Medical Writer, Healthcare Advertising Agency: £45, 000 – £50, 000

Senior Account Executive – Account Manager – Healthcare Advertis...: £32000 - £43000 Bonus Benfits

Account Director – London based Medical Communications Agency: Excellent Remuneration Package

Account Director - Medical Communications - London / South East: Excellent Salary and Benefits on offer

Account Director, Healthcare Communications: Salary TBC

Senior Account Manager > Account Director - London - Medical ...: Salary TBC

Subscribe to our email news alerts

PMHub

Add my company

Accession

Accession was a born from a passion and a vision. A passion to harness the power of market access to...

Latest intelligence

Blended Intelligence: Data is the most valued commodity of the modern world. For P&P it's all about the application....
The relevance of patient perspectives to value: Exploring the evolution of patient involvement in health technology assessment, and the role of the patient voice in market access....
How is the NHS Long-term Plan being put into action?: Steve How, Paul Midgley and Oli Hudson, of Wilmington Healthcare, explore some of the changes that have occurred since the plan was published...